Brief: Solid Biosciences Receives FDA Rare Pediatric Disease Designation For Sgt-212 Dual Route Of Administration Gene Therapy

Solid Biosciences

01/12/2025 13:31

Dec 1 (Reuters) - Solid Biosciences Inc SLDB.O:

SOLID BIOSCIENCES RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION FOR SGT-212 DUAL ROUTE OF ADMINISTRATION GENE THERAPY FOR FRIEDREICH’S ATAXIA

Source text: ID:nGNXcdnBJh

Further company coverage: SLDB.O

 ((Reuters.Briefs@thomsonreuters.com;))